Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: Can acetylcholine levels in the brain be improved in alzheimer's disease?

Drug Development Research

Volumn 14, Issue 3-4, 1988, Pages 235-246

  Becker, Robert E ^a,b   Giacobini, Ezio ^b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Souther Illinois University   (United States)

Author keywords

cortical terminals; physostigmine; senile dementia

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; METRIFONATE; PHYSOSTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; BLOOD LEVEL; BRAIN; CEREBROSPINAL FLUID; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0024152063     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.430140315     Document Type: Article

References (52)

1. Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease
2. Physostigmine and its effect on six patients with dementia
3. Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: Selective loss of the intermediate (10S) form
4. Acetylcholinesterase activityin ventricular and cisternal CSF of dogs
5. The cholinergic hypothesis of geriatric memory dysfunction
6. Mechanisms of cholinesterase inhibition in senile dementia of Alzheimer's type—clinical. pharmacological and therapeutic aspects
7. Mild senile dementia of Alzheimer type: Research diagnostic criteria, recruitment, and description of a study population
8. Alzheimer's disease a disorder of cortical cholinergic innervation
9. Cholinesterases in cerebrospinal fluid
10. Distribution of the molecular forms of acetylcholinesterase in human brain: Alterations in dementia of the Alzheimer type
11. The distribution and localization of cholinesterases in nerve cells
12. Aging of the Brain
13. Models and strategies of cholinertic therapy of Alzheimer disease
14. Models and strategies of cholinergic therapyof Alzheimer disease
15. Anticholinesterase therapy of Alzheimer: From animal models to human applications
16. Normal distribution and denervation changes of neurotransmitter related enzymes in cholinergic neurones
17. Aging of cholinergic synapses in the avian iris
18. Acetylcholine metabolism in brain. Is it reflected by CSF changes?
19. Acetylcholine metabolism in brain: Is it reflected by CSF changes?
20. Brain acetylcholine—A view from the cerebrospinal fluid (CSF)
21. Brain acetylcholine—a view from the cerebrospinal fluid
22. Pharmacokinetics and pharmacodynamics of physostigmine after I. V. administration in beagle dogs
23. Pharmacokinetics and pharmacodynamics of physostigmine after I. V. administration in beagle dogs
24. Brainacetylcholine—a view from the erebrospinal fluid
25. Quantitative assay of physostimine in human whole blood
26. Effects of physostigmine on cholinesterase activity, choline and acetylcholine levels in rat brain
27. Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat
28. A comparison of the effects of two inhibitors on brain cholinesterase
29. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients
30. The effects of physostigmine on acetylcholinesterase activity of, plasma and brain. Acomparison of i. v. and i. c. v. administration in beagle dogs
31. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
32. Oral physostigmine treatment of patients with Alzheimer's disease
33. Intravenous and oral physostigmine in Alzheimer's disease
34. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies
35. Alzheimer's Disease. Morbid risk among first‐degree relatives approximates 50% by 90 years of age
36. Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with bilarcil
37. Coenzyme a acetylating enzymes in Alzheimer's disease: Possible cholinergic compartments of pyruvate dehydrogenase
38. Epidemiology of clinically diagnosed Alzheimer's disease
39. Molecular forms of cholinesterases in cerebrospinal fluid, blood plasma, and brain tissue of the beagle dog
40. Effect of oral physostigmine in senile dementia patients: utility of blood cholinesterase inhibition and neuroendocrine responses to define pharmacokinetics and pharmacodynamics
41. Presynaptic cholinergic dysfunction in patients with dementia
42. Distribution and pharmacokinetics of physostigmine in rat after i. m. administration
43. Pharmacokinetic and pharmacodynamics of physostigmine in rat after i. v. administration
44. Accuracy of clinical diagnosis in primary degenerative dementia: Correlation with neuropathological findings
45. Hepatic and muscle clearance of physostigmine in the rat
46. Reduced lumbar CSF somatostatin levels in Alzheimer disease